Compound formula for preventing and treating obesity by comprehensively correcting metabolic disorders based on gamma-aminobutyric acid

Abstract

The invention discloses a compound formula for preventing and treating obesity by comprehensively correcting metabolic disorders based on gamma-aminobutyric acid. The compound formula comprises the components: gamma-aminobutyric acid (50-500 mg / d), nicotinic acid (20-200 mg / d), riboflavin (3-20 mg / d), pantothenic acid (5-30 mg / d), carnitine (300-2000 mg / d) and magnesium aspartate (30-500 mg / d). The gamma-aminobutyric acid in the formula inhibits nutrient absorption, protects mitochondria from being less continuously damaged by metabolic reactive oxygen species, and plays a role in less absorption and more consumption; the rest components are added to form the compound formula, beta oxidation of a fat-splitting core path is nutritionally supported, metabolism is adjusted in a mild mode, anda safe and healthy weight losing effect is achieved. In formula development, a high-throughput cell experiment and a random double-blind control multi-center volunteer experiment are comprehensivelyutilized; the action range and the toxicity threshold value of each component are accurately detected, so that the use dosage of each component has extremely high tolerance and safety, and the compound formula is suitable for being used as a core formula of a health care product or a nutritional supplement, and is beneficial to development and marketing of subsequent related products.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to a compound formula for preventing and treating obesity based on gamma-aminobutyric acid through comprehensively correcting metabolic disorders. Background technique [0002] Obesity is a chronic metabolic disorder caused by multiple factors, resulting in excessive fat content or abnormal distribution in the body. Clinically, body mass index (BMI) is used as a common indicator for judging obesity. The 2019 edition of "Guidelines for the Diagnosis and Treatment of Common Diseases at the Grassroots Level" recommends that a BMI greater than 28 be used as the diagnostic standard for obesity. The "Report on Nutrition and Chronic Disease Status of Chinese Residents" shows that the national adult overweight rate is 30.1%, and the obesity rate is 11.9%. [0003] As a metabolic disorder with a high incidence rate, obesity has a wide range of hazards. First of all, obesity has a great impact on...

AI Technical Summary

Problems solved by technology

[0007] However, the current weight loss programs on the market are one-sidedly pursuing short-term curative effects, resulting in various health problems

Among them, weight-loss drugs and health products are the hardest hit areas. First of all, some weight-loss products developed in the name of health products and functional foods have no weight-loss effect in terms of mechanism of action or actual effect, such as red bean barley powder and other products that have been marketed.

The second category is diarrhea-guiding weight-loss drugs with senna leaves as the main raw materials, which cause the body to lose water and produce the illusion of short-term weight loss, but long-term or large-scale use will cause damage to human body functions, resulting in habitual diarrhea, gastrointestinal Dysfunction and symptoms such as dehydration and electrolyte imbalance, which seriously damage the health

The third category is fat absorption inhibitors represented by orlistat, which can easily cause intestinal flora disorder and diarrhea, and anal oil leakage will also cause embarrassment and inconvenience to users

The fourth category is appetite suppressants, represented by phentermine and fenfluramine. In addition to problems such as anorexia and valvular heart disease, taking weight-loss drugs that suppress appetite may also cause abdominal pain, diarrhea, nausea and vomiting, dizziness, headache, Fatigue, fatigue, heart palpitations and other hazards

Application No. 201711061077 .X and 201711223258.8 and other patents achieve the effect of promoting metabolism through oral administration of classic weight loss auxiliary ingredients such as L-carnitine, but do not comprehensively consider the various pathways of fat metabolism, and only use one or several of them to have a slight auxiliary weight loss effect ingredients, leading to poor control effect